Literature DB >> 22834678

Drug-induced atrial fibrillation.

Yaman Kaakeh1, Brian R Overholser, John C Lopshire, James E Tisdale.   

Abstract

Atrial fibrillation (AF) is a common cardiac arrhythmia that is associated with severe consequences, including symptoms, haemodynamic instability, increased cardiovascular mortality and stroke. While other arrhythmias such as torsades de pointes and sinus bradycardia are more typically thought of as drug induced, AF may also be precipitated by drug therapy, although ascribing causality to drug-associated AF is more difficult than with other drug-induced arrhythmias. Drug-induced AF is more likely to occur in patients with risk factors and co-morbidities that commonly co-exist with AF, such as advanced age, alcohol consumption, family history of AF, hypertension, thyroid dysfunction, sleep apnoea and heart disease. New-onset AF has been associated with cardiovascular drugs such as adenosine, dobutamine and milrinone. In addition, medications such as corticosteroids, ondansetron and antineoplastic agents such as paclitaxel, mitoxantrone and doxorubicin have been reported to induce AF. Whether bisphosphonate drugs are associated with new-onset AF remains controversial and requires further study. The potential contribution of specific drug therapy should be considered when patients present with new-onset AF.

Entities:  

Mesh:

Year:  2012        PMID: 22834678      PMCID: PMC5531271          DOI: 10.2165/11633140-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  95 in total

Review 1.  Proarrhythmic effects of adenosine: one decade of clinical data.

Authors:  Amir Pelleg; Ronald S Pennock; Steven P Kutalek
Journal:  Am J Ther       Date:  2002 Mar-Apr       Impact factor: 2.688

2.  Are late potentials operative in arrhythmias following methylprednisolone pulse therapy.

Authors:  S Ozen; L Tokgozoglu; U Saatci
Journal:  Int J Cardiol       Date:  1992-08       Impact factor: 4.164

3.  Atrial fibrillation due to late amiodarone-induced thyrotoxicosis.

Authors:  Ibrahim Halil Kurt; Talat Yigit; Bulent Mustafa Karademir
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

4.  Corticosteroids and the risk of atrial fibrillation.

Authors:  Cornelis S van der Hooft; Jan Heeringa; Guy G Brusselle; Albert Hofman; Jacqueline C M Witteman; J Herre Kingma; Miriam C J M Sturkenboom; Bruno H Ch Stricker
Journal:  Arch Intern Med       Date:  2006-05-08

5.  Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report.

Authors:  Nagesha S Kasinath; Osama Malak; John Tetzlaff
Journal:  Can J Anaesth       Date:  2003-03       Impact factor: 5.063

6.  Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.

Authors:  Peter Vestergaard; Kristoffer Schwartz; Else Marie Pinholt; Lars Rejnmark; Leif Mosekilde
Journal:  Calcif Tissue Int       Date:  2010-03-23       Impact factor: 4.333

7.  Design of the Fracture Intervention Trial.

Authors:  D M Black; T F Reiss; M C Nevitt; J Cauley; D Karpf; S R Cummings
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

8.  Atrial fibrillation following methylprednisolone pulse therapy.

Authors:  N Ueda; T Yoshikawa; M Chihara; S Kawaguchi; Y Niinomi; T Yasaki
Journal:  Pediatr Nephrol       Date:  1988-01       Impact factor: 3.714

9.  High-density mapping of electrically induced atrial fibrillation in humans.

Authors:  K T Konings; C J Kirchhof; J R Smeets; H J Wellens; O C Penn; M A Allessie
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  21 in total

Review 1.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 2.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

3.  Bisphosphonates and cardiac electrophysiology: should the red flag be raised higher?

Authors:  Jérôme Kalifa; Uma Mahesh R Avula
Journal:  J Cardiovasc Electrophysiol       Date:  2014-01-24

Review 4.  Towards chamber specific heart-on-a-chip for drug testing applications.

Authors:  Yimu Zhao; Naimeh Rafatian; Erika Yan Wang; Qinghua Wu; Benjamin F L Lai; Rick Xingze Lu; Houman Savoji; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2020-01-07       Impact factor: 15.470

5.  Atrial fibrillation following treatment with paclitaxel: A case report.

Authors:  Dehua Zhao; Jing Chen; Xiaojun Liu; Xiaoqing Long; Lisha Cao; Jisheng Wang
Journal:  Biomed Rep       Date:  2018-10-12

6.  Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study).

Authors:  Wesley T O'Neal; Susan G Lakoski; Waqas Qureshi; Suzanne E Judd; George Howard; Virginia J Howard; Mary Cushman; Elsayed Z Soliman
Journal:  Am J Cardiol       Date:  2015-01-31       Impact factor: 2.778

7.  Risk factors, thromboembolic events, and clinical course of New-Onset Atrial Fibrillation among COVID-19 hospitalized patients: A multicenter cross-sectional analysis in Iran.

Authors:  Fatemeh Sadat Rahimi; Siamak Afaghi; Farzad Esmaeili Tarki; Hossein Salehi Omran; Mohammad Hossein Nasirpour
Journal:  Health Sci Rep       Date:  2022-10-17

Review 8.  Multi-lineage Human iPSC-Derived Platforms for Disease Modeling and Drug Discovery.

Authors:  Arun Sharma; Samuel Sances; Michael J Workman; Clive N Svendsen
Journal:  Cell Stem Cell       Date:  2020-03-05       Impact factor: 24.633

9.  Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.

Authors:  Wesley T O'Neal; J'Neka S Claxton; Pratik B Sandesara; Richard F MacLehose; Lin Y Chen; Lindsay G S Bengtson; Alanna M Chamberlain; Faye L Norby; Pamela L Lutsey; Alvaro Alonso
Journal:  J Am Coll Cardiol       Date:  2018-10-16       Impact factor: 24.094

10.  Chronotropic Modulation of the Source-Sink Relationship of Sinoatrial-Atrial Impulse Conduction and Its Significance to Initiation of AF: A One-Dimensional Model Study.

Authors:  Francesca Cacciani; Massimiliano Zaniboni
Journal:  Biomed Res Int       Date:  2015-07-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.